Lodine

• Nonsteroidal Antiinflammatory Agents (NSAIDs)
• ATC:M01AB08

• Etodolac [Usan:Ban:Inn]
• Etodolacetodolic acid
• Etodolaco [Inn-Spanish]
• Etodolacum [Inn-Latin]
• Etodolic Acid
• Lodine
• Lodine XL
• Ultradol

• No information avaliable

C₁₇H₂₁NO₃

http://www.rxlist.com/cgi/generic/etodolac.htm

Lodine FDA

C. A. Demerson et al., U.S. Pat. 3,939,178 (1976)

287.354 g/mol

145-148 ^oC

16 mg/L

Solid

No information avaliable

Tablet; Tablet (extended-release)

For acute and long-term use in the management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.

Etodolac, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.

Based on mass balance studies, the systemic availability of etodolac from either the tablet or capsule formulation, is at least 80%.

Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.

Lodine, like other drugs of its class, can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptom. Patients should be informed of the importance of this follow-up Effects Risk of GI Ulceration, Bleeding, and Perforation).

Patients on Lodine (etodolac capsules and tablets) should report to their physicians signs or symptoms of gastrointestinal ulceration or bleeding, blurred vision or other eye symptoms, skin rash, weight gain, or edema.

Patients should also be instructed to seek medical emergency help in case of an occurrence of anaphylactoid reactions.

Humans and other mammals